Compare Gilead Sciences, Inc. (GILD) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares Core MSCI EAFE ETF — how do they compare? Gilead Sciences, Inc. trades at $135.28 (market cap $168.35B), while iShares Core MSCI EAFE ETF trades at $100.75. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while iShares Core MSCI EAFE ETF pays none, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | IEFA | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $101.09 |
52-Week Low | $110.56 | $84.72 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IEFA (iShares Core MSCI EAFE ETF) trades at $101.09, up 1.1% with a bullish technical signal from moving averages. The fund provides exposure to developed international markets excluding the US and Canada, with a competitive 0.07% expense ratio and 3.30% dividend yield. Recent news highlights its role in diversification strategies amid S&P 500 concentration concerns.
The outlook remains positive given international diversification benefits and potential Fed rate cut catalysts. Key risks include developed market monetary policy shifts and currency fluctuations. Analyst sentiment favors IEFA for its cost efficiency and income generation, though emerging market alternatives offer different growth profiles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
